AstraZeneca stock falls after FDA panel votes against new cancer drug
CNBC1 min read
Read Full Article at CNBC →Ad Slot — In-Article (728x90)
The advisory panel wasn't convinced that a clinical trial proved that early switching to camizestrant improved long-term survival rates.
This is a summary. For the full story, read the original article at CNBC.
Original source: CNBC